Delivery Order SPE2DB22D3401-SPE2DB25FT5QA
Award Date 8/11/25
Potential Completion Date 8/12/25
Potential Value $9.4K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $6,481.97 to AmerisourceBergen Drug Corp on May 2, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injections. This firm fixed-price delivery order, with an ultimate completion date of May 5, 2025, will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award was made on a competitive basis with no set-aside designation. Zepbound is a GLP-1 receptor agonist used for chronic weight management,...
- The Defense Logistics Agency awarded a delivery order valued at $9,973.95 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injections on September 9, 2025, with an ultimate completion date of September 10, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Zepbound is a glucagon-like peptide-1 receptor agonist used in...
- The Defense Logistics Agency awarded a Delivery Order valued at $10,288.27 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injectors. This competitively awarded contract, utilizing firm fixed pricing with no set-aside designation, calls for delivery by August 8, 2025, to the contractor's facility in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication commonly prescribed for weight management and metabolic health support....
- The Defense Logistics Agency awarded a delivery order valued at $7,419.22 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pen injections on August 29, 2025, with an ultimate completion date of September 2, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and specifies performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used in diabetes and weight management...
- The Defense Logistics Agency awarded a delivery order valued at $9,371.22 to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 ml pen injections on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management and represents...
- The Defense Logistics Agency awarded a delivery order valued at $25,836.29 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injections on August 18, 2025, with an ultimate completion date of August 19, 2025. This competitively awarded, firm fixed-price delivery order utilizes no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract falls under the company's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $4,964.46 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 mL pens on July 22, 2025. This competitively awarded, firm fixed-price delivery order is set to be completed by July 23, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Zepbound is a glucagon-like peptide-1 receptor agonist used for weight management and diabetes treatment, reflecting the Defense...
- The Defense Logistics Agency awarded a delivery order valued at $30,536.46 to AmerisourceBergen Drug Corp for Zepbound 2.5 mg/0.5 mL pen injections on July 14, 2025, with an ultimate completion date of July 15, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound, a GLP-1 receptor agonist used in diabetes and weight management treatment,...
- The Defense Logistics Agency awarded a delivery order valued at $2,971.10 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injectors on August 8, 2025, with an ultimate completion date of August 11, 2025. This non-competitive, firm fixed-price delivery order was issued without a set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management...
- The Defense Logistics Agency awarded a delivery order valued at $28,363.85 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen injectors on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Zepbound, a GLP-1 receptor agonist medication used for weight management, represents...